According to a declaration published on COPE’s internet site in January 2015, these initiatives to hijack the scholarly review program were apparently orchestrated by companies that initial helped authors write or enhance their scientific articles and offered them favorable peer reviews.4 BioMed Central conducted a comprehensive investigation of most their recently published content articles and identified 43 that were published based on evaluations from fabricated reviewers. All these articles had been retracted in March 2015. The type of peer-review fraud committed by Moon, Chen, and third-party agencies could work when journals encourage or allow authors to suggest reviewers because of their own submissions.Couch, Ph.D., Melissa C. Southey, Ph.D., Robert Winqvist, Ph.D., William D. Foulkes, M.B., B.S., Ph.D., and Marc Tischkowitz, M.D., Ph.D.: Breast-Cancer Risk in Households with Mutations in PALB2 PALB2 was originally identified as a BRCA2-interacting protein that’s crucial for key BRCA2 genome caretaker features1,2; it was subsequently also shown to interact with BRCA1.5-7 In Finland, the PALB2 c.1592delT founder mutation was determined in approximately 1 percent of women with breasts cancer who were not selected based on a positive family history6 and was associated with a risk of breast cancer that was improved by a factor of 6, which is similar to the risk among carriers of deleterious BRCA2 variants in the same nation.8 In Canada, the PALB2 c.Glu775X) founder mutation was detected in approximately 0.5 percent of French-Canadian women with early-onset breast cancer who were not selected on the basis of a positive family history.9 PALB2 loss-of-function mutations have now been seen in persons from many countries and so are within 0.6 to 3.9 percent of families with a brief history of breast cancer, with respect to the population.